This issue of reproductive medicine news presents current research and data from reviews and meta-analyses on the study and innovative methods of treating diseases of the reproductive system, presented in leading international periodicals.

The present article contains the newest ant the most actual version of clinical recommendations “Obesity” of the Russian Ministry of Health. This document has been confirmed for the period until 2026 year. Obestity — is chronic disease which is characterized by excess deposition of adipose tissue and high risk of diabetes mellitus type 2 (T2DM) and cardiovascular diseases (CVD). The present version of clinical recommendation has been created due to collaboration between Russian Association of Endocrinologists and Russian Society of Bariatric Surgeons. The document is finally approved by scientific and practical Council of the Russian Ministry of Health.

The relationship between testosterone production and obesity has been found in numerous epidemiological studies. The main feature of obesity in males lies in the fact that it is abdominal obesity, i.e. deposition of adipose tissue mainly in the abdominal area, which has the consequence of affecting sex hormones metabolism. Androgen aromatization, leptin resistance, testosterone deposition, and the influence of other comorbid factors all contribute to the formation of bidirectional relationship between obesity and low testosterone levels. The increased interest in this problem has been observed in recent years, and there is data confirming the link between excess body weight and decreased testosterone levels in males. This latter data is presented in this published review. Meanwhile, reduction of body fat mass can be considered as a proposed approach to correcting hypogonadism associated with metabolic disorders, since hypogonadism in males with metabolic disorders is potentially reversible.

This review considers current ideas about the stages of development of pathological dysplastic processes in the mammary glands, data from reviews and meta-analyzes to study the causes of their development, factors of progression, the risk of their further influence on the formation of breast cancer. The use of a selective estrogen receptor modulator drug is considered as an etiopathogenetic correction of the patient’s existing disease, as its main pathological cause, and a risk factor for further proliferative and mitotic activity — long-term hyperestrogenism, the results of clinical studies in real clinical practice were evaluated.